 - Pazopanib is an oral, potent multi-targeted small-molecule inhibitor of VEGF-receptor TKs VEGFR-1 -2 -3 PDGFR and c-KIT; it is the first targeted small molecule that it has demonstrated an important activity in ovarian cancer. At ASCO 2013, the AGO-OVAR16 trial of maintenance of pazopanib in first line ovarian cancer has shown a benefit in progression free survival difference of 5.6 months of median PFS in favour of pazopanib compared to placebo Dubois, ASCO 2013 LBA5503; in this trial, the majority of the patients had few residual disease and patients did not receive bevacizumab. 